Azurity Pharmaceuticals is initiating a recall of specific ADHD and narcolepsy medication batches due to the potential inclusion of incorrect pills in the drug packages.
Azurity Pharmaceuticals Inc. initiated a recall of a batch of Zenzedi CII 30 mg pills following the discovery of carbinoxamine maleate, an antihistamine, in a bottle by a pharmacist in Nebraska, as reported by the Food and Drug Administration.
Recall ADHD Drugs- Brand and Lot Number
The company, in a recent recall announcement, specified that it is withdrawing one lot of Zanzedi 30 mg identified by lot number F230169A and an expiration date of June 2025.
This decision follows the discovery of an antihistamine, carbinoxamine maleate, in a Zanzedi package by a pharmacist.
Carbinoxamine maleate, an antihistamine utilized for allergy treatment, induces sedation in some patients, while dextroamphetamine sulfate, the intended drug in Zanzedi, functions as a stimulant, generally enhancing users’ attentiveness, as per information from Mayo Clinic.
Patients receiving the incorrect medication face an elevated risk of accidents, self-injury, drowsiness, depression, increased eye pressure, and thyroid disorders, according to Azurity’s official statement.
Notably, the pharmaceutical company clarified in its notice that no serious injury reports related to the mix-up had been received.
Prompt Return Urged for Recalled Medication
Individuals who have obtained the affected medication are advised to promptly return it to their local pharmacy.
Patients who believe they may have experienced an adverse reaction to the drug should reach out to their healthcare provider.
Additionally, reporting the medical issue to the FDA can be done by completing an online form or by calling 800-332-1088.
For inquiries related to the recall notice, consumers can contact the company at (877) 804-2069 during regular business hours, Monday through Friday, 9 a.m. to 5 p.m., Eastern time.